Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person β-adrenergic receptor agonists (β-agonists) mimic the action...
| Class:Id | Summation:9611746 |
|---|---|
| _displayName | β-adrenergic receptor agonists (β-agonists) mimic the action... |
| _timestamp | 2018-09-05 13:24:23 |
| created | [InstanceEdit:9611731] Jassal, Bijay, 2018-06-19 |
| literatureReference | [LiteratureReference:9611747] Pharmacogenetics of beta2 adrenergic receptor agonists in asthma management [LiteratureReference:9611705] The spectrum of cardiovascular effects of dobutamine - from healthy subjects to septic shock patients [LiteratureReference:9611732] Early goal-directed therapy in the treatment of severe sepsis and septic shock [LiteratureReference:9611736] Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials [LiteratureReference:9611703] Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma [LiteratureReference:9618339] Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD [LiteratureReference:9618332] Efficacy, safety, and tolerability of once-daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7-day, crossover study [LiteratureReference:9618336] Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models |
| modified | [InstanceEdit:9611924] Jassal, Bijay, 2018-06-22 [InstanceEdit:9618361] Jassal, Bijay, 2018-09-05 |
| text | β-adrenergic receptor agonists (β-agonists) mimic the action of epinephrine and norepinephrine signaling in the heart, lungs and smooth muscle tissue and have the opposite function to β-blockers. Activation of β1 receptors induces positive inotropic and chronotropic output of the cardiac muscle, leading to increased heart rate and blood pressure. Activation of β2 receptors induces smooth muscle relaxation in the lungs, GI tract, uterus and various blood vessels (Isogaya et al. 1999, Dutta & Li 2002, Ortega 2014). β-agonists are a mainstay of asthma treatment. β-agonists that bind to β1 and β2 receptors include dobutamine, arformoterol, isoprenaline and indacaterol. Dobutamine is a sympathomimetic drug (stimulant compounds which mimic the effects of endogenous agonists of the sympathetic nervous system) used in the treatment of heart failure and septic or cardiogenic shock, on the basis of its positive inotropic action (Dubin et al. 2017, Rivers et al. 2001). Arformoterol is the active (R,R)-enantiomer of formoterol and is a long-lasting β2 adrenoreceptor agonist indicated for the treatment of chronic obstructive pulmonary disease (COPD) (Sears et al. 2009). Isoprenaline (isoproterenol) is the isopropylamine analog of adrenaline and is a non-selective β-adrenoreceptor agonist used in the treatment of heart block, bradycardia and as an adjunct to treat septic shock, hypoperfusion states, congestive heart failure and cardiogenic shock. Indacaterol is an ultra-long-acting β-adrenoceptor agonist used in the treatment of COPD and asthma (Beeh et al. 2007). Abediterol is an ultra-long-acting β2-agonist currently in Phase II clinical trials that is a once-daily treatment for asthma (Beier et al. 2017) and chronic obstructive pulmonary disease (COPD) (Beier et al. 2016). It shows functional selectivity for β2 receptors over β1 receptors and is a full agonist at the β2 receptor (Aparici et al. 2012). |
| (summation) | [Reaction:9611751] β1,2-agonists bind ADRB1,2 [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by β-adrenergic receptor agonists (β-agonists) mimic the action... (9611746)
